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Introduction
Preeclampsia is a systemic and serious complication of
pregnancy that affects from 2% to 7% of all pregnancies.
It is a leading cause of maternal and perinatal mortality
and morbidity both in the western world and developing
countries [1]. This gestational disorder is characterized
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SUMMARY
Objective: Recent studies have reported that antioxidant status, including serum selenium concentrations, is altered
in women who develop preeclampsia. We wished to examine the effects of selenium supplementation in the
prevention of preeclampsia in high-risk pregnant women.
Design: We carried out a randomized, double-blind, placebo-controlled pilot trial. A total of 166 primigravid
pregnant women, who were in the first trimester of pregnancy, were randomized to receive 100 μg of selenium
(n =83; dropouts, n =22) or a placebo (n =83; dropouts, n =19) per day until delivery. The incidence of preeclamp-
sia, serum selenium concentrations, lipid profile and high-sensitivity C-reactive protein status were evaluated at
baseline and at the end of the study.
Results: Supplementation with selenium was not associated with any reported major side effects and was associ-
ated with a significant increase in mean serum selenium concentrations at term (p <0.001). In contrast, mean serum
selenium concentrations remained unchanged in the control group (p = 0.63). The incidence of preeclampsia
was lower in the selenium group (n = 0) than in the control group (n = 3), although this was not statistically 
significant (p > 0.05). After treatment, systolic and diastolic blood pressure, serum total cholesterol, triglycerides,
low-density and high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein were significantly
increased in both groups compared with pretreatment levels (p < 0.05).
Conclusion: Our findings indicate that selenium supplementation in pregnant women may be associated with a
lower frequency of preeclampsia. [Taiwan J Obstet Gynecol 2010;49(2):181–187]
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by hypertension, proteinuria, and edema, and affects
multiple organs including the liver, kidneys, brain, and
blood clotting system [2]. In spite of the severity and
prevalence of preeclampsia, the exact etiology of this dis-
order remains unknown, although impaired placental
perfusion has been proposed as a key factor [3]. Pla-
cental underperfusion and ischemia may lead to an
excessive production of reactive oxygen species and lipid
peroxides, which cause oxidative stress [4,5]. Oxidative
stress plays a critical role in endothelial cell dysfunction,
which initiates a self-progressing course and clinical
manifestations of preeclampsia including hypertension,
proteinuria, and edema [2,3,6,7]. Therefore, preeclamp-
sia can be regarded as a state of oxidative stress, and
in fact, several lines of evidence support the oxidative
hypothesis of preeclampsia. According to previous re-
ports, there is a heightened state of lipid peroxidation in
preeclamptic women, whereas the endogenous antiox-
idant defense systems such as superoxide dismutase and
glutathione peroxidase are severely depleted in these
subjects [3,5,8,9]. Based on the oxidative hypothesis of
preeclampsia, supplementation with antioxidants might
help prevent preeclampsia. One of the most important
antioxidants in the body is the trace mineral selenium,
which is an essential component of a number of antiox-
idant selenoenzymes such as glutathione peroxidase
and thioredoxin reductase [10,11]. Besides, selenium
possesses anti-inflammatory properties, which are ex-
erted through a number of mechanisms [12]. A number
of studies have reported a decrease in selenium status
during pregnancy [13–15]. Moreover, several observa-
tional studies have reported a further decrease in sele-
nium status in women with preeclampsia compared with
non-preeclamptic pregnant women [8,9,16]. However,
there are still insufficient clinical studies evaluating the
effectiveness of selenium supplementation in the pre-
vention of preeclampsia.
With regard to the numerous complications of 
preeclampsia [17,18], the significant reduction in sele-
nium status in preeclamptic women and established
antioxidant and anti-inflammatory effects of selenium,
we designed the present trial to investigate the impact
of selenium supplementation in the prevention of
preeclampsia, as well as on the lipid profile and high-
sensitivity C-reactive protein (hs-CRP) status, in high-
risk pregnant women.
Materials and Methods
Subjects
A total of 218 primigravid pregnant women aged
16–35 years were assessed for eligibility to participate
in this trial. Subjects were selected from women attend-
ing the Ommolbanin Hospital, Mashhad, Iran. The inclu-
sion criteria for selection were as follows: gestational
age up to 12 weeks, and with no indications for termi-
nation of the pregnancy. Exclusion criteria included the
use of any drugs, except routine supplements of folic
acid and ferrous sulfate, and a prior history or clinical
features of any medical conditions, including thyroid
disorders, diabetes, hypertension and infections. Thirty-
nine individuals were excluded from the study with 179
subjects entering the trial. Of these 179 subjects, 13
were excluded because of intolerance to the tablets
(n = 4) or their unpleasant aroma (n = 9).
For each participant, a questionnaire with informa-
tion about past medical history, family history of pre-
eclampsia, last menstrual period, smoking habits and
consumption of any supplement was completed. Each
subject gave written consent to participate in the study.
The study protocol was approved by the ethics com-
mittee for clinical research of the Mashhad University
of Medical Sciences.
Study design and medications
A randomized, double-blind, placebo-controlled
design was used in which the 166 eligible participants
were randomly assigned to one of the following groups:
the first group comprising 83 pregnant women who
were given 100 μg of selenium yeast daily from the first
trimester of their pregnancy until delivery for a period
of approximately 6 months (Se group), and the second
group comprising 83 pregnant women for whom daily
placebo yeast tablets were provided for the same period
(control group). A total of 125 subjects completed the
study (n = 61 and n = 64 for Se and control groups, 
respectively) (Figure). The prescribed selenium dose was
in agreement with the National Academy of Sciences’
guidelines that established an upper limit of 400 μg/day
for selenium intake [19].
Selenium yeast tablets and matched placebo yeast
tablets were provided by Pharma Nord (Vejle, Denmark).
Definition of preeclampsia and hypertension
The main outcome of our study was the incidence of
preeclampsia. We defined preeclampsia by the new
development of proteinuria. For women with pre-
existing proteinuria, the diagnosis of preeclampsia was
based on development of hypertension, as defined
below, or after identification of clinical or biochemical
markers or at least one additional feature of preeclamp-
sia such as HELLP syndrome (hemolysis, elevated liver
enzymes, and low platelet count). Hypertension was de-
fined as systolic blood pressure (SBP) = 140 mmHg and
diastolic blood pressure (DBP) = 90 mmHg according
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to the US Sixth Joint National Committee criteria 
[20]. We defined gestational hypertension as a DBP ≥
90 mmHg after 20 weeks of pregnancy or in the early
postnatal period (up to 48 hours).
Anthropometric and other measurements
Anthropometric parameters including weight, height,
and body mass index were measured. Weight was mea-
sured using a standard scale, with the subjects dressed
in light clothing after an overnight fast. Blood pressure
was measured twice using a standard mercury sphyg-
momanometer, while the patients were seated and
resting. The systolic blood pressure was defined as the
appearance of the first sound (Korotkoff phase 1) and
the diastolic blood pressure was defined as the disap-
pearance of the sound (Korotkoff phase 5) during de-
flating of the cuff. Body mass index was calculated as
weight (in kilograms) divided by the square of height
(in meters).
Lipid profile and hs-CRP
Lipid profile comprising total cholesterol, triglycerides,
low-density lipoprotein cholesterol and high-density
lipoprotein cholesterol was determined at baseline and
at the end of trial. The post-trial samples were not fast-
ing samples, while the pre-trial ones were collected after
fasting. Serum lipid profile was measured by routine
enzymatic methods using commercial kits. Serum hs-
CRP was measured by a polyethylene glycol-enhanced
immunoturbidimetric method with an Alcyon analyzer
(Abbott Laboratories, Abbott Park, IL, USA).
Serum selenium analysis
Serum selenium concentrations were determined by
electrothermal atomic absorption spectrometry with
Zeeman background correction using a palladium chlo-
ride chemical modifier. Typical between-batch precision
(coefficient of variation) was 3.7% [21,22].
Statistical analysis
All statistical analyses were performed using SPSS 
version 11.5 software (SPSS Inc., Chicago, IL, USA).
Values are expressed as mean ± standard deviation or
median and interquartile range. The group compar-
isons were assessed by χ2 test, Fisher exact test, inde-
pendent samples paired t test or Wilcoxon signed rank
test (in the case of serum triglycerides and hs-CRP). A
two-tailed p value of < 0.05 was considered statisti-
cally significant.
Results
Demographic data
There were no significant differences in age, anthropo-
metric indices, socioeconomic state, past medical history
(miscarriage and infertility history), and family history
(incidence of preeclampsia, diabetes, hypertension and
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Assessed for eligibility (n = 218) 
Completed the clinical trial  (n = 64) Completed the clinical trial  (n = 61) 
Excluded (n = 39)
Refused to participate in trial
Allocated to 100 μg/d
selenium (n = 83)
Allocated to placebo
(n = 83)
Randomized (n = 179)
Thirteen were excluded after the first
consumption of tablets because of
intolerance to selenium tablets (n = 4) and
bad smell of selenium tablets (n = 9)
Withdrew from treatment  (n = 19)
Intolerance to placebo tablets (n = 2)
Fetal miscarriage before taking placebo
tablets (n = 2) or after (n = 1)
Migration to another city (n = 1)
Spotting (n = 1)
Intake of lithium tablets (n = 1)
Failure to attend (n = 1)
Withdrew from treatment (n = 22)
Intolerance to selenium tablets (n = 2)
Fetal miscarriage before taking selenium
tablets (n = 6) or after (n = 1)
Migration to another city (n = 1)
Metrorrhagia (n = 1)
Intake of lithium tablets (n = 1)
Failure to attend (n = 9)
Car accident (n = 1)
Figure. Flow chart of the trial.
hyperlipidemia) between the Se and control groups.
Similarly, baseline SBP and DBP, lipid profile, hs-CRP
and serum selenium concentrations were not signifi-
cantly different between the Se and control groups.
There were also no significant differences between
the groups for delivery state, amniotic fluid properties,
sex of the neonate, neonatal abnormalities, age of preg-
nancy, and neonatal state. The demographic data for
the patients and controls are presented in Table 1.
Serum selenium concentrations
There was no significant difference in serum selenium
concentrations between the two groups at baseline
(Table 2). Supplementation with selenium was associ-
ated with a significant increase in serum selenium con-
centrations (p < 0.001; Table 2). In contrast, serum
selenium concentrations remained unchanged by the
end of the trial in the control group (p = 0.63; Table 2).
Effect of selenium supplementation on the incidence of
preeclampsia
There was no incidence of preeclampsia in the Se group
compared with 4.7% (n = 3) in the control group.
However, this decrease was not statistically significant,
which is probably because of the insufficient number 
of participants in the study.
Effect of selenium supplementation on lipid profile 
and serum hs-CRP
At the end of the trial, there were significant increases in
total cholesterol, triglycerides, low-density lipoprotein
cholesterol, and high-density lipoprotein cholesterol in
both the Se group (p < 0.001, p < 0.001, p < 0.001 and
p = 0.001, respectively; Table 2) and control group
(p < 0.001, p < 0.001, p < 0.001 and p = 0.007, respec-
tively; Table 2). Similar to selenium concentrations,
serum hs-CRP concentrations increased significantly in
both groups by term (p < 0.001; Table 2).
Discussion
There has been a great deal of interest in the use of
antioxidant supplementation as a preventive strategy
against preeclampsia [7,23,24]. However, the results
of trials on the efficacy of using vitamin C and vitamin E
supplementation in high-risk pregnant women have not
been promising [25,26]. Therefore, based on the current
findings, supplementation with vitamins C and E is not
recommended as part of clinical practice for reducing
the risk of preeclampsia [27].
Selenium is an essential trace element present in bio-
logic systems as a component of selenoproteins such
as glutathione peroxidase and thioredoxin reductase,
and is involved in antioxidant protection and anti-
inflammatory effects [10–12]. In cases of selenium defi-
ciency, supplementation with selenium is associated with
enhanced enzymatic antioxidant activity [28] and re-
duced lipid peroxidation [29]. Selenium concentrations
in whole blood and plasma significantly fall during preg-
nancy compared with pre-pregnancy or non-pregnancy
concentrations, and this decrease is progressive as 
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Table 1. Demographic characteristics of selenium (Se) and control groups at baseline*
Se group (n = 83) Control group (n = 83) p
Age (yr) 21.6 ± 2.5 21.6 ± 3.4 0.91
Weight (kg) 58.5 ± 10.2 56.5 ± 9.8 0.16
Height (cm) 156.7 ± 5.8 156.7 ± 6.3 0.99
BMI (kg/m2) 23.8 ± 3.8 23.0 ± 4.0 0.16
Waist circumference (cm) 77.1 ± 11.6 74.9 ± 8.2 0.13
Hip circumference (cm) 95.8 ± 12.1 94.8 ± 7.9 0.50
Waist to hip ratio 0.8 ± 0.08 0.8 ± 0.06 0.14
Education 0.89
Illiterate or lower than diploma 42 (50.6) 44 (53.0)
Diploma 36 (43.4) 35 (42.2)
Higher than diploma 5 (6.0) 4 (4.8)
Family history
Preeclampsia 11 (13.3) 18 (21.7) 0.13
Diabetes 2 (2.4) 5 (6.0) 0.17
Hypertension 5 (6.0) 5 (6.0) 0.93
Hyperlipidemia 4 (4.8) 5 (6.0) 0.79
*Data are presented as mean ± standard deviation or n (%). BMI = body mass index.
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Table 2. Comparison of clinical and biochemical parameters pre- and post-trial*†
Parameters
Se group Control group
Pre-trial Post-trial p‡ Pre-trial Post-trial p‡
SBP (mmHg) 100.1 ± 10.5 111.4 ± 8.6 < 0.001 101.9 ± 11.4 111.2 ± 11.1 0.002
DBP (mmHg) 62.5 ± 8.4 70.2 ± 9.2 < 0.001 62.9 ± 11.5 69.2 ± 9.4 0.03
Cholesterol (mg/dL) 177.3 ± 60.2 222.4 ± 50.2 < 0.001 165.9 ± 53.4 206.1 ± 50.3 < 0.001
TG (mg/dL) 88.0 (62.0–98.0) 211.0 (141.7–245.2) < 0.001 80.0 (73.0–103.0) 181.5 (144.5–223.5) < 0.001
LDL-C (mg/dL) 113.8 ± 55.0 132.0 ± 41.2 < 0.001 104.4 ± 49.8 115.2 ± 23.2 < 0.001
HDL-C (mg/dL) 48.8 ± 10.4 59.3 ± 11.0 0.001 46.8 ± 8.6 58.6 ± 10.1 0.007
hs-CRP (mg/L) 5.2 (1.5–7.6) 25.4 (8.8–52.1) < 0.001 4.1 (1.8–7.6) 43.3 (8.9–89.3) < 0.001
Se (μg/L) 122.5 ± 23.2 168.6 ± 36.4 < 0.001 122.9 ± 26.9 119.4 ± 33.4 0.63
Incidence of 0 (0) 3 (4.7) 0.25§
preeclampsia, n (%)
*Data are presented as mean ± standard deviation or median (interquartile range); †pre-trial samples but not post-trial samples were collected fasted; ‡paired 
t test or Wilcoxon signed rank test; §Fisher exact test. Se = selenium; SBP = systolic blood pressure; DBP = diastolic blood pressure; TG = triglycerides; LDL-C =
low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein.
gestation proceeds [13–15]. Furthermore, epidemio-
logic studies have shown that selenium status in pre-
eclamptic patients is significantly decreased both in
serum and toenail specimens [8,9,16]. As expected,
the activity of glutathione peroxidase is also decreased
in preeclampsia as a function of selenium depletion
[30]. In spite of these findings, there are few clinical
trials investigating the efficacy of selenium supplemen-
tation in preventing the incidence of preeclampsia. The
results of our trial suggested that selenium supplemen-
tation is associated with a decrease in the incidence of
preeclampsia in pregnant women at risk of developing
the disease. However, the small number of participants
in our study is a limiting factor that may have led to
this decrease being nonsignificant.
To the best of our knowledge, there has been only
one trial investigating the influence of selenium sup-
plementation in preeclamptic women. In this study,
Han and Zhou [31] reported the beneficial effect of
supplementation with 100 μg of selenium per day in
the prevention of pregnancy-induced hypertension
and gestational edema in a group of Chinese pregnant
women. Their study population comprised 100 preg-
nant women at high risk of preeclampsia (n = 52 in 
the Se group and n = 48 in the control group) in cer-
tain selenium deficient regions of China that had been
previously reported to have a high prevalence of
preeclampsia [31].
The low incidence of preeclampsia in our study pop-
ulation, in spite of the greater number of participants
compared with the only similar previous study [31], is
probably due to the relatively high serum selenium con-
centrations. The mean serum selenium concentrations
in our study are higher than those reported in most parts
of Europe, including the United Kingdom [32–35].
Mean selenium concentrations in our study are even
higher than reported values in other provinces of Iran,
and are similar to the selenium status in the popula-
tion of North America [36–39].
In the current study, the increase in lipid profile
parameters in both groups is consistent with previous
reports and could be attributed to the hormonal chan-
ges during pregnancy and effect of female sexual hor-
mones, in particular estrogen, on lipid metabolism [40].
During pregnancy, the activity of hepatic lipase is in-
creased and that of lipoprotein lipase is decreased,
which lead to the elevation of triglyceride concentra-
tions [40]. These changes in lipid parameters are even
more remarkable during preeclampsia, and as a result,
a casual relationship has been proposed between dys-
lipidemia, in particular hypertriglyceridemia, and the
development of preeclampsia [41,42]. However, the
hypothesis that dyslipidemia always precedes the clinical
manifestations of preeclampsia and may be used as a
predictor of the disorder is still inconsistent and has
been not confirmed by the findings of some studies,
including our study [43]. The increase in hs-CRP con-
centrations in both groups in our study could be due
to the profound inflammatory changes during preg-
nancy as described elsewhere [44]. However the increase
in the Se group was less than that in controls, which is
probably because of the effect of selenium on hs-CRP
status and the inverse relationship that exists between
them [45,46]. Another important explanation for the
rise of these parameters is that the post-trial samples
were not fasting samples while the pre-trial ones were
collected after fasting.
In summary, the findings of the present ran-
domized, double blind, placebo-controlled pilot trial
indicate that selenium supplementation in Iranian
pregnant women, who have a higher selenium status
than those of UK and other European countries, is safe
and may be associated with a lower incidence of pre-
eclampsia. The main limitation of our pilot study was
the relatively small study population. Therefore, any
definitive judgment about the efficacy of selenium
supplementation in pregnancy for the purpose of pre-
venting the development of preeclampsia will depend
on the results of future trials with a larger number of
participants.
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